Richard S. Judson
Chief Tech/Sci/R&D Officer at Genaissance Pharmaceuticals, Inc.
Richard S. Judson active positions
| Companies | Position | Start | End |
|---|---|---|---|
Genaissance Pharmaceuticals, Inc.
 Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Chief Tech/Sci/R&D Officer | 31/01/1999 | - |
Career history of Richard S. Judson
Former positions of Richard S. Judson
| Companies | Position | Start | End |
|---|---|---|---|
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Corporate Officer/Principal | 31/12/1996 | 31/01/1999 |
Training of Richard S. Judson
| Rice University | Undergraduate Degree |
| Princeton University | Doctorate Degree |
Statistics
International
| United States | 5 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Genaissance Pharmaceuticals, Inc.
Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
- Stock Market
- Insiders
- Richard S. Judson
- Experience
